register

News & Trends - Biotechnology

Parliament House hosts biotech policy forum

Health Industry Hub | November 17, 2023 |

Biotech News: Canberra’s Parliament House hosted biotech leaders for strategic discussions and insightful presentations. The AusBiotech annual Policy Forum marked a significant collaboration between industry and government officials, underscoring the vital intersection of capital, policy and innovation shaping the evolving biotechnology landscape.

The 2023 CEO delegation, comprising Amplia Therapeutics, BioDiem, CSL, Esfam Biotech, Microbio, SpeeDx, Relix Pharmaceuticals, UniQuest, Vaxxas, and others, focussed on pivotal discussions revolving around the vitality of financial capital, deemed the ‘lifeblood’ nurturing the growth of the biotech sector. These discussions delved into capital attraction initiatives and opportunities outlined in the Biotechnology Blueprint.

In attendance were The Hon Ed Husic (MP), Minister for Industry and Science, along with notable representatives from the Department of Health and Aged Care, the Department of Industry, Science and Resources, and Treasury.

The AusBiotech CEO Policy Forum served as a pivotal platform for biotech leaders to gain insights into the government’s objectives. Simultaneously, it provided a unique opportunity for government officials to delve deeper into the impact of life sciences on the nation’s economy.

Central to the discussions were key policy areas that underpin the biotech sector’s progress, including the implications of quantum advancements on biotech, policy mechanisms to allure greater private investments, and the scope of government funding within the industry. A CEO workshop further fostered discussions on proactive policy initiatives aimed at supporting industry-driven medical research, effectively charting the trajectory for AusBiotech’s future policy endeavours and advocacy work.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Government's rejection of COVID Royal Commission a stark contrast to the UK and NZ

Government’s rejection of COVID Royal Commission a stark contrast to the UK and NZ

Health Industry Hub | September 20, 2024 |

The Albanese government has dismissed the Senate legal and constitutional committee’s proposal for a COVID-19 pandemic royal commission with one […]

More


News & Trends - Biotechnology

AusBiotech and MTPConnect Unite for Landmark Summit on Australia’s Biotech and Medtech Future

AusBiotech and MTPConnect unite for landmark Summit on the nation’s biotech and medtech future

Health Industry Hub | September 20, 2024 |

AusBiotech and MTPConnect have announced an ambitious new collaboration to host Australia’s first National Biotech and Medtech Development and Commercialisation […]

More


ESG

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Health Industry Hub | September 20, 2024 |

Today marks the first ever national Wear It Red Day. An initiative of Painaustralia, the national peak advocacy body for […]

More


News & Trends - Pharmaceuticals

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients: New study

Health Industry Hub | September 20, 2024 |

Pharma News: New research from the led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) […]

More


This content is copyright protected. Please subscribe to gain access.